LA MARCA, Antonio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 25.896
AS - Asia 9.025
EU - Europa 8.277
SA - Sud America 1.688
AF - Africa 175
OC - Oceania 74
Continente sconosciuto - Info sul continente non disponibili 15
Totale 45.150
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.637
SG - Singapore 2.969
GB - Regno Unito 2.727
CN - Cina 2.268
HK - Hong Kong 1.771
BR - Brasile 1.362
IT - Italia 1.326
SE - Svezia 1.117
DE - Germania 810
VN - Vietnam 655
UA - Ucraina 576
RU - Federazione Russa 487
TR - Turchia 396
BG - Bulgaria 240
FI - Finlandia 240
KR - Corea 166
FR - Francia 152
IN - India 149
ID - Indonesia 146
AR - Argentina 142
CA - Canada 129
NL - Olanda 102
JP - Giappone 88
MX - Messico 85
ES - Italia 83
ZA - Sudafrica 60
RO - Romania 58
EC - Ecuador 57
IQ - Iraq 56
PL - Polonia 56
AU - Australia 54
IR - Iran 50
BD - Bangladesh 47
IE - Irlanda 40
PK - Pakistan 39
LT - Lituania 35
CO - Colombia 33
CZ - Repubblica Ceca 30
BE - Belgio 29
AT - Austria 28
UZ - Uzbekistan 27
PH - Filippine 26
CL - Cile 25
PY - Paraguay 23
MY - Malesia 22
VE - Venezuela 22
MA - Marocco 21
CH - Svizzera 20
EG - Egitto 20
DZ - Algeria 19
NZ - Nuova Zelanda 17
AE - Emirati Arabi Uniti 15
AL - Albania 15
DK - Danimarca 15
TH - Thailandia 15
KE - Kenya 14
HR - Croazia 13
TW - Taiwan 13
IL - Israele 12
PE - Perù 12
SA - Arabia Saudita 12
JO - Giordania 11
NO - Norvegia 11
KZ - Kazakistan 10
LV - Lettonia 10
CR - Costa Rica 9
DO - Repubblica Dominicana 9
GR - Grecia 9
MD - Moldavia 9
NP - Nepal 9
TN - Tunisia 9
AZ - Azerbaigian 7
EU - Europa 7
HU - Ungheria 7
NG - Nigeria 6
PA - Panama 6
AM - Armenia 5
HN - Honduras 5
PS - Palestinian Territory 5
PT - Portogallo 5
SC - Seychelles 5
SK - Slovacchia (Repubblica Slovacca) 5
UY - Uruguay 5
A2 - ???statistics.table.value.countryCode.A2??? 4
BA - Bosnia-Erzegovina 4
BO - Bolivia 4
GH - Ghana 4
KW - Kuwait 4
LB - Libano 4
MN - Mongolia 4
RS - Serbia 4
SI - Slovenia 4
SN - Senegal 4
ET - Etiopia 3
GT - Guatemala 3
JM - Giamaica 3
MK - Macedonia 3
PR - Porto Rico 3
XK - ???statistics.table.value.countryCode.XK??? 3
BB - Barbados 2
Totale 45.097
Salva come PNG Salva come JPEG
Città #
Fairfield 3.903
Ashburn 2.461
Santa Clara 2.204
Woodbridge 1.886
Singapore 1.838
Hong Kong 1.744
Southend 1.737
Houston 1.574
Seattle 1.470
Cambridge 1.304
Wilmington 1.170
Chandler 1.125
Jacksonville 899
Ann Arbor 758
Dearborn 681
Nyköping 675
London 610
Hefei 590
Beijing 490
Modena 389
Los Angeles 311
Chicago 286
San Diego 286
Ho Chi Minh City 254
Princeton 237
Sofia 234
Izmir 206
New York 200
Eugene 193
Moscow 175
Boardman 160
The Dalles 155
Helsinki 133
Seoul 133
Buffalo 129
Shanghai 127
São Paulo 120
Bremen 119
Hanoi 117
Jakarta 106
Salt Lake City 99
Council Bluffs 98
Munich 87
Dallas 84
Milan 76
Redwood City 68
Redondo Beach 65
Tampa 65
Rome 63
Bologna 60
Tokyo 56
Guangzhou 55
Columbus 50
Amsterdam 49
Frankfurt am Main 43
Rio de Janeiro 43
Toronto 42
Elk Grove Village 41
Falls Church 40
Phoenix 40
Warsaw 39
Norwalk 37
Dublin 36
Johannesburg 36
Denver 34
Kilburn 34
Stockholm 34
Montreal 33
Nanjing 33
Atlanta 32
Fremont 32
Melbourne 32
Iasi 31
Brooklyn 29
Belo Horizonte 27
Turku 27
Kunming 26
Mexico City 26
Brasília 25
Ankara 24
Haiphong 24
Jinan 24
Parma 24
San Francisco 24
Tashkent 24
Augusta 23
Boston 23
Nuremberg 23
Salvador 23
Biên Hòa 21
Da Nang 21
Porto Alegre 21
Dong Ket 20
Dulles 20
Fuzhou 20
Orem 20
Paris 20
Philadelphia 20
Poplar 20
Quito 20
Totale 33.475
Salva come PNG Salva come JPEG
Nome #
Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial 582
Anti-Mullerian hormone (AMH): what do we still need to know? 432
MATER protein as substrate of PKCepsilon in human cumulus cells. 383
LH and hCG Action on the Same Receptor Results in Quantitatively and Qualitatively Different Intracellular Signalling 339
Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). 328
Chronic endometritis in recurrent implantation failure: Use of prednisone and IVF outcome 313
Age-specific nomogram for the decline in antral follicle count throughout the reproductive period 309
Vitamin D and ovarian reserve: making clinical decisions 298
The anti-Müllerian hormone (AMH) acts as a gatekeeper of ovarian steroidogenesis inhibiting the granulosa cell response to both FSH and LH 297
Embryo quality and implantation rate in two different culture media: ISM1 versus Universal IVF Medium. 294
From a circle to a sphere: the ultrasound imaging of ovarian follicle with 2D and 3D technology 290
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 285
The menstrual cycle regularization following d-chiro-inositol treatment in PCOS women: a retrospective study 284
FSHR polymorphism p.N680S mediates different responses to FSH in vitro 283
Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice 282
Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: An individual patient data approach 280
Modulation of gonadotrophin induced steroidogenic enzymes in granulosa cells by d-chiroinositol 278
Evidence for expression and functionality of FSH and LH/hCG receptors in human endometrium 278
Human ovarian tissue cryopreservation: effect of sucrose concentration on morphological features after thawing 275
Gene expression profiles of human granulosa cells treated with bioequivalent doses of corifollitropin alfa (CFA) or recombinant human follicle-stimulating hormone (recFSH) 275
How Much Does AMH Really Vary in Normal Women? 271
Female age, serum antimüllerian hormone level, and number of oocytes affect the rate and number of euploid blastocysts in in vitro fertilization/intracytoplasmic sperm injection cycles 270
A novel transnational fresh oocyte donation (TOD) program based on transport of frozen sperm and embryos 270
Age-specific reference values for serum FSH and estradiol levels throughout the reproductive period 265
Individualization of the FSH starting dose in IVF/ICSI cycles using the antral follicle count 265
Anti-Mullerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool? 264
Development of a nomogram based on markers of ovarian reserve for the individualisation of the follicle-stimulating hormone starting dose in in vitro fertilisation cycles 264
Anti-Mullerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology 261
Elevated levels of nitrous dioxide are associated with lower AMH levels: A real-world analysis 261
Polymorphisms in gonadotropin and gonadotropin receptor genes as markers of ovarian reserve and response in in vitro fertilization 260
Adnexal torsion during pregnancy after oocyte in vitro maturation and intracytoplasmic sperminjection cycle 258
New strategies of ovarian stimulation based on the concept of ovarian follicular waves: From conventional to random and double stimulation 256
Periodontal disease and nitric oxide levels in low risk women with preterm labor 254
The anti-Müllerian hormone (AMH) induces forkhead box L2 (FOXL2) expression in primary culture of human granulosa cells in vitro 254
Reference values in ovarian response to controlled ovarian stimulation throughout the reproductive period 253
Nitric Oxide concentration in endometrial washing throughout the menstrual cycle 252
Age-related normograms of serum antimüllerian hormone levels in a population of infertile women: a multicenter study 251
Evidence for cycle-dependent expression of follicle-stimulating hormone receptor in human endometrium 251
Utero-vaginal anastomosis in the treatment of cervical atresia 249
The ovarian response to controlled stimulation in IVF cycles may be predictive of the age at menopause 247
Live birth rates in the different combinations of the Bologna criteria poor ovarian responders: a validation study 246
Primary ovarian insufficiency: autoimmune causes. 245
Prediction of age at menopause from assessment of ovarian reserve may be improved by using body mass index and smoking status. 243
Seminal plasma total antioxidant capacity and semen parameters in patients with varicocele 242
Membrane Estrogen Receptor (GPER) and Follicle-Stimulating Hormone Receptor (FSHR) Heteromeric Complexes Promote Human Ovarian Follicle Survival 241
Corrigendum to “Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV” [J Hepatol 68 (2018) 33–41](S0168827817322596)(10.1016/j.jhep.2017.08.019) 239
Ovarian response markers lead to appropriate and effective use of corifollitropin alpha in assisted reproduction 238
Does plasma insulin level affect ovarian response to exogenous administration of follicle-stimulating hormone in women without polycystic ovary syndrome? 237
A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles 237
Anti-Mullerian hormone concentrations in maternal serum during pregnancy 236
Adrenal adenocarcinoma and empty sella syndrome in a 37-year-old woman 231
Administration of L-thyroxine does not improve the response of the hypothalamo-pituitary-ovarian axis to clomiphene citrate in functional hypothalamic amenorrhea 230
Anti-Mullerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation 229
Anti-Müllerian hormone-based prediction model for a live birth in assisted reproduction 228
How to personalize ovarian stimulation in clinical practice 228
Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome 228
Rectovaginal fistula repair using fascia graft of autologous abdominal muscles 227
The ovarian follicular pool and reproductive outcome in women. 226
Administration of somatostatin analogue reduces uterine and myoma volume in women with uterine leiomyomata 224
ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria 223
Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: An individual patient data meta-analysis 223
8th World Congress of Gynecological Endocrinology 222
The combination of genetic variants of the FSHB and FSHR genes affects serum FSH in women of reproductive age 221
Evaluation of the treatment with D-chiroinositol on levels of oxidative stress in PCOS patients 221
External validation of anti-Müllerian hormone based prediction of live birth in assisted conception 220
Rectus abdominis muscle endometriosis: Case report and review of the literature 220
Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI) 218
The use of ovarian reserve markers in IVF clinical practice: a national consensus 216
Increased risk of preterm birth and low birthweight with very high number of oocytes following IVF: an analysis of 65 868 singleton live birth outcomes 216
Normal serum anti-Müllerian hormone levels in the general female population and the relationship with reproductive history 215
The management of vaginal agenesis: report of 104 cases 213
Metformin treatment of PCOS during adolescence and the reproductive period 211
Endocrine and metabolic effects of octreotide, a somatostatin analogue, in lean PCOS patients with either hyperinsulinaemia or lean normoinsulinaemia 211
Advances in the Molecular Pathophysiology, Genetics, and Treatment of Primary Ovarian Insufficiency 211
Reply: The two sides of the individualization of controlled ovarian stimulation 210
Clomiphene citrate increases insulin-like growth factor binding protein-1 and reduces insulin-like growth factor-I without correcting insulin resistance associated with polycystic ovarian syndrome 209
Clinical application of a nomogram based on age, serum FSH and AMH to select the FSH starting dose in IVF/ICSI cycles: a retrospective two-centres study 209
Thyroid function in early pregnancy II: Paradoxical growth hormone response to thyrotropin-releasing hormone 209
Hormonal and ultrasound markers of ovarian function in a woman with a balanced 1;11 translocation 208
Gestrinone in the treatment of uterine leiomyomata: effects on uterine blood supply 208
The FSHR polymorphism p.N680S mediates different response kinetics to FSH in vitro 208
The physiology and clinical utility of anti-Mullerian hormone in women 207
Short-term treatment of uterine fibromyomas with danazol 206
Surgical treatment of ovarian dermoid cysts 205
Recombinant LH administration in subsequent cycle after "unexpected" poor response to recombinant FSH monotherapy 203
Anti-mullerian hormone in premenopausal women and after spontaneous or surgically induced menopause 203
Progestin effects on epidermal growth factor receptor (EGFR) endometrial expression in normal and hyperplastic endometrium 202
Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients 201
Effects of estradiol alone or in combination with cyproterone acetate on carotid artery pulsatility index in postmenopausal women 201
Pyrexia, leukocytosis and elevated circulating platelets associated to uterine stromal sarcoma with rhabdoid differentiation 201
Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome 201
Recombinant human leptin in women with hypothalamic amenorrhea. 200
Veralipride administered in combination with raloxifene decreases hot flushes and improves bone density in early postmenopausal women 200
Whatever its variability, antimüllerian hormone remains the most stable hormonal predictor 199
Insulin sensitizing agents and their effect on adrenal androgens?: the reply 199
Evaluation of plasma levels of renin-aldosterone and blood pressure in women over 35 years treated with new oral contraceptives 199
Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome 198
Possibilities and Limits of Ovarian Reserve Testing in ART 198
Perinatal outcomes following IVF with use of donor versus partner sperm 198
Ultrastructural and DNA fragmentation analyses in swim-up selected human sperm 197
Totale 24.556
Salva come PNG Salva come JPEG
Categoria #
all - tutte 195.193
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 195.193
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.401 0 0 0 0 0 374 570 871 261 699 353 273
2021/20224.566 176 862 513 160 84 175 345 216 415 356 872 392
2022/20233.625 454 416 349 293 473 434 82 308 414 39 174 189
2023/20243.007 95 153 122 270 479 180 510 456 68 95 131 448
2024/20258.209 260 89 107 581 1.510 1.099 434 449 1.158 519 786 1.217
2025/20268.211 1.057 530 1.581 2.000 2.208 835 0 0 0 0 0 0
Totale 45.583